Century Therapeutics, Inc. Operating Income
Century Therapeutics, Inc. (IPSC) reported Operating Income of -$36.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Century Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$36.53M.
- Century Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$23.68M, a 131.93% decline year-over-year.
- Century Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$20.65M.
- Century Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$36.12M.
- Century Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$17.27M.
- Century Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$138.14M.
- Century Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$146.55M.
- Century Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$133.83M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.53M 10-Q · filed 2026-08-12 | -$60.21M 10-Q · filed 2026-08-12 | -$80.86M derived: sum of 3 quarters · filed 2026-08-12 | -$116.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$23.68M 10-Q · filed 2026-05-13 | -$44.34M derived: sum of 2 quarters · filed 2026-05-13 | -$80.46M derived: sum of 3 quarters · filed 2026-05-13 | -$115.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$20.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$56.77M derived: sum of 2 quarters · filed 2026-03-12 | -$91.44M derived: sum of 3 quarters · filed 2026-08-12 | -$17.27M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$36.12M 10-Q · filed 2025-11-13 | -$70.79M derived: sum of 2 quarters · filed 2026-08-12 | $3.38M 10-Q · filed 2025-11-13 | -$33.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$34.66M 10-Q · filed 2026-08-12 | $39.51M 10-Q · filed 2026-08-12 | $2.23M derived: sum of 3 quarters · filed 2026-08-12 | -$32.56M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $74.18M 10-Q · filed 2026-05-13 | $36.89M derived: sum of 2 quarters · filed 2026-05-13 | $2.10M derived: sum of 3 quarters · filed 2026-05-13 | -$32.65M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$37.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$72.07M derived: sum of 2 quarters · filed 2026-03-12 | -$106.83M derived: sum of 3 quarters · filed 2026-03-12 | -$138.14M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$34.79M 10-Q · filed 2025-11-13 | -$69.54M derived: sum of 2 quarters · filed 2025-11-13 | -$100.85M 10-Q · filed 2025-11-13 | -$144.62M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$34.76M 10-Q · filed 2025-08-14 | -$66.07M 10-Q · filed 2025-08-14 | -$109.83M derived: sum of 3 quarters · filed 2025-08-14 | -$145.45M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$31.31M 10-Q · filed 2025-05-15 | -$75.07M derived: sum of 2 quarters · filed 2025-05-15 | -$110.70M derived: sum of 3 quarters · filed 2025-05-15 | -$145.77M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$43.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$79.39M derived: sum of 2 quarters · filed 2025-03-19 | -$114.47M derived: sum of 3 quarters · filed 2025-03-19 | -$146.55M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$35.63M 10-Q · filed 2024-11-05 | -$70.70M derived: sum of 2 quarters · filed 2024-11-05 | -$102.78M 10-Q · filed 2024-11-05 | -$136.09M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$35.08M 10-Q · filed 2024-08-08 | -$67.16M 10-Q · filed 2024-08-08 | -$100.46M derived: sum of 3 quarters · filed 2024-08-08 | -$132.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$32.08M 10-Q · filed 2024-05-09 | -$65.39M derived: sum of 2 quarters · filed 2024-05-09 | -$97.13M derived: sum of 3 quarters · filed 2024-05-09 | -$128.48M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$33.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$65.04M derived: sum of 2 quarters · filed 2024-03-14 | -$96.39M derived: sum of 3 quarters · filed 2024-03-14 | -$133.83M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$31.74M 10-Q · filed 2023-11-09 | -$63.09M derived: sum of 2 quarters · filed 2023-11-09 | -$100.53M 10-Q · filed 2023-11-09 | -$128.50M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$31.35M 10-Q · filed 2023-08-09 | -$68.79M 10-Q · filed 2023-08-09 | -$96.76M derived: sum of 3 quarters · filed 2023-08-09 | -$122.59M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$37.44M 10-Q · filed 2023-05-11 | -$65.41M derived: sum of 2 quarters · filed 2023-05-11 | -$91.24M derived: sum of 3 quarters · filed 2023-05-11 | -$114.26M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$27.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$53.80M derived: sum of 2 quarters · filed 2023-03-16 | -$76.82M derived: sum of 3 quarters · filed 2023-03-16 | -$94.88M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$25.83M 10-Q · filed 2022-11-10 | -$48.85M derived: sum of 2 quarters · filed 2022-11-10 | -$66.91M 10-Q · filed 2022-11-10 | -$82.17M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$23.02M 10-Q · filed 2022-08-11 | -$41.08M 10-Q · filed 2022-08-11 | -$56.34M derived: sum of 3 quarters · filed 2022-08-11 | -$69.47M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$18.06M 10-Q · filed 2022-05-16 | -$33.32M derived: sum of 2 quarters · filed 2022-05-16 | -$46.45M derived: sum of 3 quarters · filed 2022-05-16 | -$61.97M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$28.39M derived: sum of 2 quarters · filed 2022-03-17 | -$43.91M derived: sum of 3 quarters · filed 2022-03-17 | -$53.90M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$13.13M 10-Q · filed 2021-11-10 | -$28.65M derived: sum of 2 quarters · filed 2021-11-10 | -$38.64M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$15.52M 10-Q · filed 2021-08-12 | -$25.51M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |